Pediatric Oncology
Blocking Fructose Metabolism Shows Promise Against Pediatric Brain Cancer
New research from Johns Hopkins reveals that disrupting fructose metabolism in tumor cells could slow group 3 medulloblastoma, a deadly childhood brain cancer, offering a potential new treatment avenue.
FDA Guidance Accelerates Lantern Pharma's Pediatric Brain Cancer Therapy Development
Lantern Pharma received FDA guidance that will help advance its LP-184/STAR-001 therapy for rare pediatric brain cancers toward clinical trials planned for 2026, representing significant progress in treating conditions with limited options.
University of Florida Student Joshua Cottle Wins 2024 Friedman & Simon Academic Scholarship for His Inspiring Journey from Cancer Survivor to Aspiring Pediatric Oncologist
Joshua Cottle, a biology major at the University of Florida, has been awarded the $1,500 Friedman & Simon Academic Scholarship for his inspiring journey overcoming large-cell lymphoma and his commitment to supporting other young cancer patients through his pursuit of pediatric oncology.
Lantern Pharma Receives FDA Guidance for Pediatric CNS Cancer Trial, Advancing AI-Driven Oncology Treatment
Lantern Pharma has completed a Type C meeting with the FDA, gaining regulatory guidance for its planned pediatric trial targeting CNS cancers including ATRT, which could accelerate development of its AI-driven oncology therapy LP-184/STAR-001.
New Study Offers Hope for Pediatric Glioma Treatment
A collaborative study between the Broad Institute and the Dana-Farber Cancer Institute has identified a promising treatment approach for pediatric gliomas using FDA-approved inhibitors.
Research Uncovers Early Development Patterns of Pediatric Brain Tumors
A new study explores the complex origins of medulloblastoma in specialized nerve cells, potentially offering insights for future treatment strategies in pediatric brain cancer.